União Europeia - português - EMA (European Medicines Agency)

novartis europharm limited - ranibizumab - wet macular degeneration; macular edema; diabetes complications; myopia, degenerative; choroidal neovascularization - oftalmológicos - lucentis é indicado em adultos para o tratamento de neovascular (úmida) degeneração macular relacionada à idade (amd)o tratamento da deficiência visual, devido a choroidal neovascularisation (cnv)o tratamento da deficiência visual, devido ao diabético macular, edema (dme)o tratamento da deficiência visual, devido à macular, edema secundário à oclusão da veia da retina (ramo rvo ou central rvo).

União Europeia - português - EMA (European Medicines Agency)

samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - oftalmológicos - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

União Europeia - português - EMA (European Medicines Agency)

stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmológicos - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

União Europeia - português - EMA (European Medicines Agency)

midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmológicos - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).

União Europeia - português - EMA (European Medicines Agency)

rotterdam biologics b.v. - bevacizumab - degeneração macular úmida - oftalmológicos - treatment of neovascular (wet) age-related macular degeneration (amd).

Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

novartis biociencias s.a - ranibizumabe - outros medicamentos com acao no aparelho visual